Effect of Vitamin D Supplementation on Psoriasis Severity in Patients With Lower-Range Serum 25-Hydroxyvitamin D Levels: A Randomized Clinical Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of psoriasis and psoriatic arthritis.

To examine the effect of vitamin D supplementation on psoriasis severity throughout the winter.

Why It Was Studied

Topical vitamin D analogues are routine treatment for psoriasis, but the effect of oral supplementation has not been established.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, women only.

All participants, health care clinicians, and outcome assessors were masked to group assignment.

Adults from the general population in Tromsø with active plaque psoriasis and 25-hydroxyvitamin D (25[OH]D) levels of less than 24 ng/mL (to convert to nmol/L, multiply by 2.496) were included.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

This randomized, double-blind placebo-controlled clinical trial with 2 parallel groups was performed through 2 winter seasons (2017 to 2018 and 2018 to 2019).

The presented analyses were conducted in May 2022.

The trial was conducted at the clinical research unit of the University Hospital of North Norway (Tromsø; Norway).

What Was Measured

Topics PubMed links to this paper include Vitamin D, Cholecalciferol, Vitamins, Psoriasis and Dietary Supplements.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with psoriasis and psoriatic arthritis.

Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (JAMA dermatology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Psoriasis and psoriatic arthritis research.